DOI: 10.20286/ijtmgh-030111 International Journal of Travel Medicine and Global Health

http://journals.bmsu.ac.ir/ijtmgh Int J Travel Med Glob Health. 2015;3(1):11-17

Original Article Open Access

Low Dose Celecoxib Combined with Clozapine for Treatment of

Schizophrenia: A Double Blind Randomized Clinical Trial

1. Department of Psychiatry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2. Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 3. Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 4. Department of Psychiatry, School of Public Health, University of Michigan, Ann Arbor, USA

*Corresponding Author: Ali Akhoundpour Manteghi, Ibn-e-Sina Hospital, Faculty of Medicine, Mashhad University of Medical Sciences,

Mashhad, Iran

Email: manteghia@mums.ac.ir

Abstract

1. Introduction

http://ijtmgh.ir/mailto:manteghia@mums.ac.ir

1. Sadock BJ, Sadock VA. Kaplan & Sadock’s comprehensive textbook

of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins;

2009, pp. 1432-1629.

2. Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine

action in the CNS: implications for psychiatric disorders. Prog Neu-

ropsychopharmacol Biol Psychiatry. 1998;22(1):1-33.

3. Monji A. The neuroinflammation hypothesis of psychiatric disorders.

Seishin Shinkeigaku Zasshi. 2012;114(2):124-33. [Article in Japa-

nese]

4. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased inter-

leukin-1 and interleukin-3 like activity in schizophrenic patients.

Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(1):75-83.

5. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, et al.

Inflammation in patients with schizophrenia: the therapeutic benefits

of risperidone plus add-on dextromethorphan. J Neuroimmune Phar-

macol. 2012;7(3):656-64.

6. Licino J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated

CSF levels of interleukin-2 in neuroleptic-free schizophrenic pa-

tients. Am J Psychiatry. 1993;150(9):1408-10.

7. McAllister CG, Van Kammen DP, Rehn TJ, Miller AL, Gurklis J,

Kelley ME, Yao J, Peters JL. Increases in CSF levels of interleukin–

2 in schizophrenia: effects of recurrence of psychosis and medication

status. Am J Psychiatry. 1995;152(9):1291-7.

8. Müller N, Dobmeier P, Empl M, Riedel M, Schwarz M, Ackenheil

M. Soluble IL-6 receptors in the serum and cerebrospinal fluid of pa-

raniod schizophrenic patients. Eur Psychiatry. 1997;12(6):294-9.

9. Van Kammen DP, McAllister-Sistilli CG, Kelley ME. Relationship

between immune and behavioral measures in schizophrenia. In:

Wieselmann G (ed) Current Update in Psychoimmunology Springer

Verlag Wien: NY, 1997, pp. 51-55.

10. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil

M, Möller HJ, et al. COX-2 inhibition as a treatment approach in

schizophrenia: immunological considerations and clinical effects of

celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci.

2004;254(1):14-22.

11. Müller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of

COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry

Clin Neurosci. 2005;255(2):149-51.

12. Müller N, Strassnig M, Schwarz MJ, Ulmschneider M, Riedel M.

COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert

Opin Investig Drugs. 2004;13(8):1033-44.

13. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA. Cyclooxygenase-2

contributes to N-methyl-D-aspartate-mediated neuronal cell death in

primary cortical cell culture. J Pharmacol Exp Ther.

2000;293(2):417-25.

14. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S,

Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ.

Beneficial antipsychotic effects of celecoxib add-on therapy com-

pared to risperidone alone in schizophrenia. Am J Psychiatry.

2002;159(6):1029-34.

15. Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M. Neuroleptic

treatment increases soluble IL-2 receptors and decreases soluble IL-

6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci.

1997;247(6):308-13.

16. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R,

Altamura C, Scharpé S, Maes M. The inflammatory response system

in treatment-resistant schizophrenia: increased serum interleukin-6.

Schizophr Res. 1998;32(1):9-15.

17. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. IL-2 and

IL-6 in schizophrenia and mania: effects of neuroleptics and mood

stabilizers. J Psychiatr Res. 1995;29(2):141-52.

18. Yermakova A, Banion MK. Cyclooxygenases in the Central Nervous

System: implication for treatment of neurogical disorders. Curr

Pharm Des. 2000;6(17):1755-6.

19. Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizo-

phrenia: a promising neuroimmunological target for the treatment of

negative/cognitive symptoms and beyond. Pharmacol

Ther. 2011;132(1):96-110.

20. Hochberg MC. COX-2 selective inhibitors in the treatment of arthri-

tis: a rheumatologist perspective. Curr Top Med

Chem. 2005;5(5):443-8.

21. McGeer PL. COX –2 inhibitors: rationale and therapeutic potential

for Alzheimer’s disease. Drug Aging. 2000;17(1):1-11.

22. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Ab-

basi SH, Behnam B. Celecoxib as adjunctive therapy in schizophre-

nia: a double-blind, randomized and placebo-controlled trial. Schiz-

ophr Res. 2007;90(1-3):179-85.

23. Mizuno M, Sotoyama H, Narita E, Kawamura H, Namba H, Zheng

Y, Eda T, Nawa H. A cyclooxygenase-2 inhibitor ameliorates behav-

ioral impairments induced by striatal administration of epidermal

growth factor. J Neurosci. 2007;27(38):10116-27.

24. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O,

Dolnak D. Celecoxib augmentation of continuously ill patients with

schizophrenia. Biol Psychiatry. 2005;57(12):1594-6.

25. Stolk P, Souverein PC, Leufkens HG, Weil JG, Egberts AC, Heerdink

ER. The association between exposure to COX-2 inhibitors and

schizophrenia deterioration. A nested case-control study. Pharma-

copsychiatry. 2007;40(3):111-5.

26. Ginovart N, Kapur S. Role of dopamine d(2) receptors for antipsy-

chotic activity. Handb Exp Pharmacol. 2012;(212):27-52.

27. Partitt K. Martindale: the complete drug reference. 32nd ed. Massa-

chusetts: Pharmacological Press; 1999. pp. 63-6, 657-60.

28. Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J. Immuno-

modulatory effects of clozapine and their clinical implications: what

have we learned so far?. Schizophr Res. 2012;140(1-3):204-13.

29. Meltzer HY. Update on Typical and Atypical Antipsychotic Drugs.

Annu Rev Med. 2013;64:393-406.

30. Hardman IG, Limbard LE. Goodman & Gilman’s the Pharmacologi-

cal Basis of Therapeutics. 10th ed. New York: Mc Graw – Hill; 2001.

pp. 485-500, 715.

31. Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as tar-

gets for drugs useful to treat psychosis and cognitive impairment in

schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1572-86.

32. Suzuki T, Remington G, Mulsant BH, et al. Treatment resistant schiz-

ophrenia and response to antipsychotics: a review. Schizophr

Res. 2011;133(1–3):54-62.

33. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclo-oxygenase-2 selective in-

hibitors aggravate kainic and induced seizure and neuronal cell death

in the hippocampus. Brain Res. 1999; 843(1-2):118-29.

34. Lantz MS, Giambanco V. Acute onset of auditory hallucination after

initiation of celecoxib therapy. Am J Psychiatry. 2000;157(6):1022-

3.

35. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome

Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276.

36. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the

positive and negative syndrome scale for schizophrenics. Psychiatry

Res. 1988;23(1):99-110.

37. Kianmanesh S, Jenaabadi H. The study of difference between the fre-

quency of positive and negative symptoms of schizophrenia in people

with different cultural backgrounds. Glob J Scientific Res.

2014;2(5):124-7.

38. Müller N, Riedel M, Schwarz MJ. Psychotropic effects of COX-2 in-

hibitors--a possible new approach for the treatment of psychiatric dis-

orders. Pharmacopsychiatry. 2004;37(6):266-9.

39. Bresee CJ, Delrahim K, Maddux RE, Dolnak D, Ahmadpour O, Ra-

paport MH. The effects of celecoxib augmentation on cytokine levels

in schizophrenia. Int J Neuropsychopharmacol. 2006;9(3):343-8.

40. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa

H, Kanba S. The effect of atypical antipsychotics, perospirone,

http://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%BCller%20N%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ackenheil%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Psychoneuroimmunology%20and%20the%20cytokine%20action%20in%20the%20CNS%3A%20implication%20for%20psychiatric%20disordershttp://www.ncbi.nlm.nih.gov/pubmed?term=Psychoneuroimmunology%20and%20the%20cytokine%20action%20in%20the%20CNS%3A%20implication%20for%20psychiatric%20disordershttp://www.ncbi.nlm.nih.gov/pubmed?term=Monji%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22568115http://www.ncbi.nlm.nih.gov/pubmed/22568115http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sirota%20P%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schild%20K%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Elizur%20A%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Djaldetti%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Fishman%20P%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Increased%20interleukin-1%20and%20interleukin-3%20like%20activity%20in%20schizophrenic%20patientshttp://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20SL%5BAuthor%5D&cauthor=true&cauthor_uid=22730040http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20SY%5BAuthor%5D&cauthor=true&cauthor_uid=22730040http://www.ncbi.nlm.nih.gov/pubmed?term=Chang%20YH%5BAuthor%5D&cauthor=true&cauthor_uid=22730040http://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20SH%5BAuthor%5D&cauthor=true&cauthor_uid=22730040http://www.ncbi.nlm.nih.gov/pubmed?term=Chu%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=22730040http://www.ncbi.nlm.nih.gov/pubmed?term=Tzeng%20NS%5BAuthor%5D&cauthor=true&cauthor_uid=22730040http://www.ncbi.nlm.nih.gov/pubmed/22730040http://www.ncbi.nlm.nih.gov/pubmed/22730040http://www.ncbi.nlm.nih.gov/pubmed?term=Elevated%20CSF%20levels%20of%20interleukin-2%20in%20neuroleptic-free%20schizophrenic%20patientshttp://www.ncbi.nlm.nih.gov/pubmed?term=%22McAllister%20CG%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22van%20Kammen%20DP%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Rehn%20TJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Miller%20AL%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Gurklis%20J%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Kelley%20ME%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Yao%20J%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Peters%20JL%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Increases%20in%20CSF%20levels%20of%20interleukin%E2%80%932%20in%20schizophrenia%3A%20effects%20of%20recurrence%20of%20psychosis%20and%20medication%20statushttp://www.ncbi.nlm.nih.gov/pubmed/19698539http://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%BCller%20N%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ulmschneider%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Scheppach%20C%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schwarz%20MJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ackenheil%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ackenheil%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%B6ller%20HJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=COX-2%20inhibition%20as%20a%20treatment%20approach%20in%20schizophrenia%3A%20immunological%20considerations%20and%20clinical%20effects%20of%20celecoxib%20add-on%20therapyhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%BCller%20N%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Riedel%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schwarz%20MJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Engel%20RR%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/15549344http://www.ncbi.nlm.nih.gov/pubmed/15549344http://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%BCller%20N%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Strassnig%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schwarz%20MJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ulmschneider%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Riedel%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/15268640http://www.ncbi.nlm.nih.gov/pubmed/15268640http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hewett%20SJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Uliasz%20TF%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Vidwans%20AS%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Hewett%20JA%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Cyclooxygenase-2%20contributes%20to%20N-methyl-D-aspartate-mediated%20neuronal%20cell%20death%20in%20primary%20cortical%20cell%20culturehttp://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%BCller%20N%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Riedel%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Scheppach%20C%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Brandst%C3%A4tter%20B%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Sokullu%20S%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Krampe%20K%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ulmschneider%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Engel%20RR%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%B6ller%20HJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schwarz%20MJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/12042193http://www.ncbi.nlm.nih.gov/pubmed/12042193http://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%BCller%20N%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Empl%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Riedel%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schwarz%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ackenheil%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Neuroleptic%20treatment%20increases%20soluble%20IL-2%20receptors%20and%20decreases%20soluble%20IL-6%20receptors%20in%20schizophrenia.http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lin%20A%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Kenis%20G%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bignotti%20S%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Tura%20GJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22De%20Jong%20R%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bosmans%20E%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Pioli%20R%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Altamura%20C%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Scharp%C3%A9%20S%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Maes%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=The%20inflammatory%20response%20system%20in%20treatment-resistant%20schizophrenia%3A%20increased%20serum%20interleukin-6.%20http://www.ncbi.nlm.nih.gov/pubmed?term=%22Maes%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bosmans%20E%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Calabrese%20J%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Smith%20R%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Meltzer%20HY%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=IL-2%20and%20IL-6%20in%20schizophrenia%20and%20mania%3A%20effects%20of%20neuroleptics%20and%20mood%20%E2%80%93%20stabilizershttp://www.ncbi.nlm.nih.gov/pubmed?term=Meyer%20U%5BAuthor%5D&cauthor=true&cauthor_uid=21704074http://www.ncbi.nlm.nih.gov/pubmed?term=Schwarz%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=21704074http://www.ncbi.nlm.nih.gov/pubmed?term=M%C3%BCller%20N%5BAuthor%5D&cauthor=true&cauthor_uid=21704074http://www.ncbi.nlm.nih.gov/pubmed/21704074http://www.ncbi.nlm.nih.gov/pubmed/21704074http://www.ncbi.nlm.nih.gov/pubmed?term=Hochberg%20MC%5BAuthor%5D&cauthor=true&cauthor_uid=15974939http://www.ncbi.nlm.nih.gov/pubmed/15974939http://www.ncbi.nlm.nih.gov/pubmed/15974939http://www.ncbi.nlm.nih.gov/pubmed?term=%22Akhondzadeh%20S%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Tabatabaee%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Amini%20H%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ahmadi%20Abhari%20SA%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Abbasi%20SH%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Abbasi%20SH%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Behnam%20B%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/17208413http://www.ncbi.nlm.nih.gov/pubmed/17208413http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mizuno%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Sotoyama%20H%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Narita%20E%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Kawamura%20H%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Namba%20H%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Zheng%20Y%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Zheng%20Y%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Eda%20T%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Nawa%20H%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/17881518http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rapaport%20MH%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Delrahim%20KK%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bresee%20CJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Maddux%20RE%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ahmadpour%20O%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolnak%20D%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/15953498http://www.ncbi.nlm.nih.gov/pubmed?term=%22Stolk%20P%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Souverein%20PC%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Leufkens%20HG%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Weil%20JG%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Egberts%20AC%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Heerdink%20ER%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Heerdink%20ER%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/17541886http://www.ncbi.nlm.nih.gov/pubmed/17541886http://www.ncbi.nlm.nih.gov/pubmed?term=Ginovart%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23129327http://www.ncbi.nlm.nih.gov/pubmed?term=Kapur%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23129327http://www.ncbi.nlm.nih.gov/pubmed/23129327http://www.ncbi.nlm.nih.gov/pubmed?term=R%C3%B8ge%20R%5BAuthor%5D&cauthor=true&cauthor_uid=22831769http://www.ncbi.nlm.nih.gov/pubmed?term=M%C3%B8ller%20BK%5BAuthor%5D&cauthor=true&cauthor_uid=22831769http://www.ncbi.nlm.nih.gov/pubmed?term=Andersen%20CR%5BAuthor%5D&cauthor=true&cauthor_uid=22831769http://www.ncbi.nlm.nih.gov/pubmed?term=Correll%20CU%5BAuthor%5D&cauthor=true&cauthor_uid=22831769http://www.ncbi.nlm.nih.gov/pubmed?term=Nielsen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22831769http://www.ncbi.nlm.nih.gov/pubmed/22831769http://www.ncbi.nlm.nih.gov/pubmed?term=Meltzer%20HY%5BAuthor%5D&cauthor=true&cauthor_uid=23020880http://www.ncbi.nlm.nih.gov/pubmed/23020880http://www.ncbi.nlm.nih.gov/pubmed?term=Meltzer%20HY%5BAuthor%5D&cauthor=true&cauthor_uid=22283753http://www.ncbi.nlm.nih.gov/pubmed?term=Massey%20BW%5BAuthor%5D&cauthor=true&cauthor_uid=22283753http://www.ncbi.nlm.nih.gov/pubmed?term=Horiguchi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22283753http://www.ncbi.nlm.nih.gov/pubmed/22283753http://www.ncbi.nlm.nih.gov/pubmed?term=%22Baik%20EJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Kim%20EJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Lee%20SH%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Moon%20C%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/9705828http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giambanco%20V%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Kay%20SR%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Opler%20LA%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Lindenmayer%20JP%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/3363019http://www.ncbi.nlm.nih.gov/pubmed/3363019http://www.ncbi.nlm.nih.gov/pubmed?term=%22M%C3%BCller%20N%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Riedel%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schwarz%20MJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/15551192http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bresee%20CJ%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Delrahim%20K%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Maddux%20RE%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolnak%20D%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ahmadpour%20O%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Rapaport%20MH%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Rapaport%20MH%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/16035956http://www.ncbi.nlm.nih.gov/pubmed?term=Bian%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=17716796http://www.ncbi.nlm.nih.gov/pubmed?term=Kato%20T%5BAuthor%5D&cauthor=true&cauthor_uid=17716796http://www.ncbi.nlm.nih.gov/pubmed?term=Monji%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17716796http://www.ncbi.nlm.nih.gov/pubmed?term=Hashioka%20S%5BAuthor%5D&cauthor=true&cauthor_uid=17716796http://www.ncbi.nlm.nih.gov/pubmed?term=Mizoguchi%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=17716796http://www.ncbi.nlm.nih.gov/pubmed?term=Horikawa%20H%5BAuthor%5D&cauthor=true&cauthor_uid=17716796http://www.ncbi.nlm.nih.gov/pubmed?term=Horikawa%20H%5BAuthor%5D&cauthor=true&cauthor_uid=17716796http://www.ncbi.nlm.nih.gov/pubmed?term=Kanba%20S%5BAuthor%5D&cauthor=true&cauthor_uid=17716796

ziprasidone and quetiapine on microglial activation induced by inter-

feron-gamma. Prog Neuropsychopharmacol Biol Psychia-

try. 2008;32(1):42-8.

41. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA,

Davis CM. Effects of smoking on haloperidol and reduced haloperi-

dol plasma concentrations and haloperidol clearance. Psychopharma-

cology (Ber). 1986;90(4):468-70.

42. Dysken MW, Cumming RJ, Channon RA, Davis JM. Drug interac-

tion between ascorbic acid and fluphenazine. JAMA.

1979;241(19):2008.

43. Kulhanek F, Linde OK, Meisenberg G. Precipitation of antipsychotic

drugs in interaction with coffee or tea. Lancet. 1979;1(8152):1130-1.

44. Bowen S, Taylor KM, Gibb IA. Effect of coffee and tea on blood

levels and efficacy of antipsychotic drugs. Lancet

1981;1(8231):1217-18.

45. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-

inflammatory drugs in schizophrenia: ready for practice or a good

start? A meta-analysis. J Clin Psychiatry. 2012;73(4):414-9.

46. Krebs M, Leopold K, Hinzpeter A, Schaefer M. Neuroprotective

agents in schizophrenia and affective disorders. Expert Opin Pharma-

cother. 2006;7(7):837-48.

http://www.ncbi.nlm.nih.gov/pubmed/17716796http://www.ncbi.nlm.nih.gov/pubmed/17716796http://www.ncbi.nlm.nih.gov/pubmed?term=Sommer%20IE%5BAuthor%5D&cauthor=true&cauthor_uid=22225599http://www.ncbi.nlm.nih.gov/pubmed?term=de%20Witte%20L%5BAuthor%5D&cauthor=true&cauthor_uid=22225599http://www.ncbi.nlm.nih.gov/pubmed?term=Begemann%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22225599http://www.ncbi.nlm.nih.gov/pubmed?term=Kahn%20RS%5BAuthor%5D&cauthor=true&cauthor_uid=22225599http://www.ncbi.nlm.nih.gov/pubmed/22225599http://www.ncbi.nlm.nih.gov/pubmed?term=%22Krebs%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Leopold%20K%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Hinzpeter%20A%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schaefer%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/16634707http://www.ncbi.nlm.nih.gov/pubmed/16634707